Use of dupilumab for atopic dermatitis in young transplant patients-A case series of 3 patients

Patients who undergo solid organ transplantation are at an increased risk of developing atopic dermatitis, potentially due to long-term use of calcineurin inhibitors which results in a shift towards the Th2 immune response. The effectiveness and safety of dupilumab for atopic dermatitis in posttrans...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2023-09, Vol.40 (5), p.897-899
Main Authors: Steele, Maritza V, Gupta, Rachit, Maguiness, Sheilagh, Boull, Christina
Format: Article
Language:English
Subjects:
Atopic dermatitis
Calcineurin inhibitors
Eczema
Immune response
Lymphocytes T
Monoclonal antibodies
Pediatrics
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients who undergo solid organ transplantation are at an increased risk of developing atopic dermatitis, potentially due to long-term use of calcineurin inhibitors which results in a shift towards the Th2 immune response. The effectiveness and safety of dupilumab for atopic dermatitis in posttransplant patients is not established. Previous reports of dupilumab use in posttransplant patients have been in adult patients. In this series, we report three young posttransplant patients treated successfully with dupilumab.
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.15280